EUVIMEDEUVIMED entdecken
Crossref

Ferritin-encapsulated iron oxide nanoparticles for dual-mode MRI contrast enhancement and targeted cancer imaging

Junying Zhang, Xuelu Peng, Jian Liu, Shangpo Yang, Haiyan Xu, Minmin Liang

Analytica Chimica Acta · 2026-01 · 1382 · 344863

DOI: 10.1016/j.aca.2025.344863 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Analytica Chimica Acta, 2026-01. Verfasst von Junying Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Experimental Center of Advanced Materials, School of Materials Science & Engineering, Beijing Institute of Technology, Beijing, PR China. Hauptthemen laut MEDLINE: Magnetic Resonance Imaging, Contrast Media, Ferritins, Magnetic Iron Oxide Nanoparticles. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Beijing Institute of Technology Research Fund Program for Young Scholars, National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Magnetic Resonance Imaging (MRI) is a crucial non-invasive diagnostic tool, yet its inherent contrast limitations often necessitate the use of exogenous agents. Conventional gadolinium-based contrast agents suffer from toxicity and limited specificity. RESULTS: In this study, we present Fe3O4@HFn, an ultrasensitive MRI contrast agent composed of human ferritin (HFn) encapsulating iron oxide nanoparticles. Fe3O4@HFn enables dual-mode longitudinal relaxation time (T1) and transverse relaxation time (T2) contrast enhancement, significantly outperforming Gd-DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid), a commonly used clinical MRI contrast agent, at both 3.0 T and 11.7 T. At 3.0 T, Fe3O4@HFn exhibits 1.56-fold and 40.1-fold higher longitudinal relaxation rate (r1 = 5.20 s-1mM-1) and transverse relaxation rate (r2 = 147.6 s-1mM-1), respectively. At 11.7 T, it maintains superior relaxation rates (r1 = 0.85 s-1mM-1, r2 = 178.0 s-1mM-1). Mechanistic studies demonstrated efficient tumor targeting via TfR1 receptor-mediated endocytosis in U87 glioma and HL60 leukemia cells. In vivo, Fe3O4@HFn exhibited high selectivity, excellent biocompatibility, and promising potential for early cancer detection and therapeutic monitoring. SIGNIFICANCE: This work pioneers the integration of human ferritin nanocages with magnetic nanocores for precise, non-invasive cancer imaging, offering a transformative approach to early tumor detection and monitoring, and addressing critical safety and sensitivity limitations of existing MRI contrast agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Magnetic Resonance ImagingContrast MediaFerritinsMagnetic Iron Oxide NanoparticlesHumansAnimalsMiceCell Line, Tumor

Stichwörter der Autor:innen

Dual-mode T(1)/T(2) imagingFerritin-based nanoparticlesMRI contrast agentRelaxivity enhancementTumor diagnostics and monitoring

Substanzen

Contrast MediaFerritins

Autor:innen und Institutionen

  • Experimental Center of Advanced Materials, School of Materials Science & Engineering, Beijing Institute of Technology, Beijing, PR China.
  • Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, PR China.
  • Department of Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, PR China.
  • Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, PR China. Electronic address: xuhy@pumc.edu.cn.
  • Experimental Center of Advanced Materials, School of Materials Science & Engineering, Beijing Institute of Technology, Beijing, PR China. Electronic address: mmliang@bit.edu.cn.

Förderung

  • National Natural Science Foundation of China
  • Beijing Institute of Technology Research Fund Program for Young Scholars
  • National Key Research and Development Program of China

Zitieren

APA

Zhang, J., Peng, X., Liu, J., Yang, S., Xu, H., & Liang, M. (2026). Ferritin-encapsulated iron oxide nanoparticles for dual-mode MRI contrast enhancement and targeted cancer imaging. Analytica Chimica Acta, 1382, 344863. https://doi.org/10.1016/j.aca.2025.344863

Vancouver

Zhang J, Peng X, Liu J, Yang S, Xu H, Liang M. Ferritin-encapsulated iron oxide nanoparticles for dual-mode MRI contrast enhancement and targeted cancer imaging. Analytica Chimica Acta. 2026;1382:344863. doi:10.1016/j.aca.2025.344863

BibTeX
@article{Zhang2026,
  author = {Zhang, Junying and Peng, Xuelu and Liu, Jian and Yang, Shangpo and Xu, Haiyan and Liang, Minmin},
  title = {Ferritin-encapsulated iron oxide nanoparticles for dual-mode MRI contrast enhancement and targeted cancer imaging},
  journal = {Analytica Chimica Acta},
  year = {2026},
  volume = {1382},
  pages = {344863},
  doi = {10.1016/j.aca.2025.344863}
}
Kostenlos starten →